Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the safety of YFV in patients with CIMID, considering the immunosuppression degree conferred by the treatment used. It was not possible to establish recommendations on the effectiveness of YFV in these patients as there is no consistent evidence to support these recommendations. Conclusion: This paper approaches a real need, assessed by clinicians and patient care groups, to address specific questions on the management of YFV in patients with CIMID living or traveling to YF endemic areas, involving specialists from many areas together with patients, and might have global applicability, contributing to and supporting vaccination practices. We recommended a shared decision-making approach on taking or not the YFV

Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 – Treatment

Universidade Federal de Pernambuco. Recife, PE, Brasil; Universidade Federal de Pernambuco. Hospital das Clínicas. Recife, PE, Brasil; Universidade Federal de Pernambuco. Hospital das Clínicas. Serviço de Reumatologia. Recife, PE, Brasil; Instituto de Medicina Integral Professor Fernando Figueira. Recife, PE, Brasil; Hospital Getúlio Vargas. Ambulatório de Chikungunya. Recife, PE, Brasil; Universidade Federal da Paraíba. João Pessoa, PB, Brasil; Universidade Federal da Paraíba. Hospital Universitário Lauro Wanderley. Serviço de Reumatologia. João Pessoa, PB, Brasil; Universidade Estadual de Ciências da Saúde de Alagoas. Maceió, AL, Brasil; Universidade Federal do Rio Grande do Norte. Natal, RN, Brasil; Universidade Federal do Ceará. Faculdade de Medicina. Departamento de Medicina Clínica. Fortaleza, CE, Brasil; Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil; Universidade Estadual do Piauí. Faculdade de Medicina. Teresina, PI, Brasil; Universidade Federal de Sergipe. Aracaju, SE, Brasil; Universidade do Estado do Rio de Janeiro. Disciplina de Reumatologia. Rio de Janeiro, RJ, Brasil; Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sérgio Arouca. Rio de Janeiro, RJ, Brasil; Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Rio de Janeiro, RJ, Brasil; Hospital dos Servidores do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil; Hospital Estadual Eduardo Rabello. Serviço de Reumatologia. Rio de Janeiro, RJ, Brasil; Universidade Federal do Amazonas. Faculdade de Medicina. Manaus, AM, Brasil; Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brasil; Universidade Federal de Mato Grosso do Sul. Hospital Universitário Maria Aparecida Pedrossian. Serviço de Reumatologia. Campo Grande, MS, Brasil; Universidade de São Paulo. Faculdade de Medicina de Ribeirão Preto. Serviço de Reumatologia e Imunologia Pediátrica. Ribeirão Preto, SP, Brasil; Universidade Federal de São Paulo. São Paulo, SP, Brasil; Universidade de Santo Amaro. São Paulo, SP, Brasil; Universidade de São Paulo. Hospital das Clínicas. Ambulatório da Divisão de Moléstias Infecciosas de Parasitárias. São Paulo, SP, Brasil; Instituto de Medicina Integral Professor Fernando Figueira. Hospital Miguel Arraes. Paulista, PE, Brasil; Universidade Federal de Pernambuco. Hospital das Clínicas. Divisão de Gestão do Cuidado. Recife, PE, Brasil; CRP Fisioterapia. Rio de Janeiro, RJ, Brasil; Universidade Estadual do Piauí. Teresina, PI, Brasil; Sociedade Brasileira de Reumatologia. São Paulo, SP, Brasil; Santa Casa de Misericórdia de Maceió. Maceió, AL, BrasilSubmitted by Fátima Lopes ([email protected]) on 2017-10-24T13:42:18Z No. of bitstreams: 1 RecomendaçõesSociedadeBrasileiraP2.pdf: 984331 bytes, checksum: 9e4f277be0f65c545e7ac6b277aac848 (MD5)Approved for entry into archive by Fátima Lopes ([email protected]) on 2017-10-24T13:58:50Z (GMT) No. of bitstreams: 1 RecomendaçõesSociedadeBrasileiraP2.pdf: 984331 bytes, checksum: 9e4f277be0f65c545e7ac6b277aac848 (MD5)Made available in DSpace on 2017-10-24T13:58:50Z (GMT). No. of bitstreams: 1 RecomendaçõesSociedadeBrasileiraP2.pdf: 984331 bytes, checksum: 9e4f277be0f65c545e7ac6b277aac848 (MD5) Previous issue date: 2017Multipla - ver em NotasA febre chikungunya tem se tornado um importante problema de saúde pública nos países onde ocorrem as epidemias, visto que metade dos casos evolui com artrite crônica, persistente e incapacitante. Os dados na literatura sobre terapêuticas específicas nas diversas fases da artropatia ocasionada pela infecção pelo vírus chikungunya (CHIKV) são limitados, não existem estudos randomizados de qualidade que avaliem a eficácia das diferentes terapias. Há algumas poucas publicações sobre o tratamento das manifestações musculoesqueléticas da febre chikungunya, porém com importantes limitações metodológicas. Os dados atualmente disponíveis não permitem conclusões favoráveis ou contrárias a terapêuticas específicas, bem como uma adequada avaliação quanto à superioridade entre as diferentes medicações empregadas. O objetivo deste trabalho foi elaborar recomendações para o tratamento da febre chikungunya no Brasil. Foi feita uma revisão da literatura com seleção de artigos baseados em evidência, nas bases de dados Medline, SciELO, PubMed e Embase e de resumos de anais de congressos, além da opinião dos especialistas para dar apoio às decisões tomadas para definir as recomendações. Para a definição do grau de concordância foi feita uma metodologia Delphi, em duas reuniões presenciais e várias rodadas de votação on line. Este artigo refere-se à parte 2 das Recomendações da Sociedade Brasileira de Reumatologia para Diagnóstico e Tratamento da Febre Chikungunya, que trata especificamente do tratamento

Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 - Diagnosis and special situations

Abstract Chikungunya fever has become a relevant public health problem in countries where epidemics occur. Until 2013, only imported cases occurred in the Americas, but in October of that year, the first cases were reported in Saint Marin island in the Caribbean. The first autochthonous cases were confirmed in Brazil in September 2014; until epidemiological week 37 of 2016, 236,287 probable cases of infection with Chikungunya virus had been registered, 116,523 of which had serological confirmation. Environmental changes caused by humans, disorderly urban growth and an ever-increasing number of international travelers were described as the factors responsible for the emergence of large-scale epidemics. Clinically characterized by fever and joint pain in the acute stage, approximately half of patients progress to the chronic stage (beyond 3 months), which is accompanied by persistent and disabling pain. The aim of the present study was to formulate recommendations for the diagnosis and treatment of Chikungunya fever in Brazil. A literature review was performed in the MEDLINE, SciELO and PubMed databases to ground the decisions for recommendations. The degree of concordance among experts was established through the Delphi method, involving 2 in-person meetings and several online voting rounds. In total, 25 recommendations were formulated and divided into 3 thematic groups: (1) clinical, laboratory and imaging diagnosis; (2) special situations; and (3) treatment. The first 2 themes are presented in part 1, and treatment is presented in part 2

Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 - Treatment

Abstract Chikungunya fever has become an important public health problem in countries where epidemics occur because half of the cases progress to chronic, persistent and debilitating arthritis. Literature data on specific therapies at the various phases of arthropathy caused by chikungunya virus (CHIKV) infection are limited, lacking quality randomized trials assessing the efficacies of different therapies. There are a few studies on the treatment of musculoskeletal manifestations of chikungunya fever, but these studies have important methodological limitations. The data currently available preclude conclusions favorable or contrary to specific therapies, or an adequate comparison between the different drugs used. The objective of this study was to develop recommendations for the treatment of chikungunya fever in Brazil. A literature review was performed via evidence-based selection of articles in the databases Medline, SciELO, PubMed and Embase and conference proceedings abstracts, in addition to expert opinions to support decision-making in defining recommendations. The Delphi method was used to define the degrees of agreement in 2 face-to-face meetings and several online voting rounds. This study is part 2 of the Recommendations of the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia - SBR) for the Diagnosis and Treatment of chikungunya fever and specifically addresses treatment